Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.61 |
| ▸ | PPARG | P37231 | 6/20 | 0.35 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | PPARD | Q03181 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995238 | 0.80 | GRM2 (0.68) | GRM2PPARGPPARAPPARD | |
| SCHEMBL1997237 | 0.79 | GRM2 (0.71) | GRM2PPARGPPARAPPARD | |
| SCHEMBL1998223 | 0.78 | GRM2 (0.70) | GRM2 | |
| SCHEMBL2001373 | 0.77 | GRM2 (0.71) | GRM2 | |
| SCHEMBL1997138 | 0.77 | GRM2 (0.65) | GRM2PPARGPPARAPPARD | |
| SCHEMBL1996029 | 0.77 | GRM2 (1.00) | GRM2 | |
| SCHEMBL1993438 | 0.77 | GRM2 (0.61) | GRM2PPARGPPARAPPARD | |
| SCHEMBL1997576 | 0.76 | GRM2 (0.60) | GRM2PPARGPPARAPPARD | |
| SCHEMBL1996315 | 0.76 | GRM2 (0.65) | GRM2PPARGPPARAPPARD | |
| SCHEMBL1998513 | 0.74 | GRM2 (0.76) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | GRM2 1/4885PPARG 98/4885PPARA 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.